Clinical trials
Phase 1 Neoplasms trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
146 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 9 |
| 2017 | 12 |
| 2018 | 9 |
| 2019 | 13 |
| 2020 | 8 |
| 2021 | 9 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 9 |
| 2025 | 7 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
| Active, not recruiting | 28 |
| Terminated | 27 |
| Recruiting | 17 |
| Unknown status | 6 |
| Enrolling by invitation | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 27 |
| GlaxoSmithKline | 18 |
| Amgen | 7 |
| Hoffmann-La Roche | 5 |
| Merck Sharp & Dohme LLC | 5 |
| Bristol-Myers Squibb | 4 |
| Novartis Pharmaceuticals | 4 |
| Pfizer | 4 |
| Adaptimmune | 3 |
| Atridia Pty Ltd. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 146 |
| Carcinoma, Non-Small-Cell Lung | 27 |
| Neoplasm Metastasis | 19 |
| Colorectal Neoplasms | 18 |
| Melanoma | 15 |
| Breast Neoplasms | 13 |
| Ovarian Neoplasms | 12 |
| Lymphoma, Non-Hodgkin | 10 |
| Carcinoma, Renal Cell | 9 |
| Triple Negative Breast Neoplasms | 9 |
Trials
Showing 1 to 25 of 146. Each trial links to its page on Pharma Observatory.
46 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.